Skip to main navigation
Skip to search
Skip to main content
Ariel University Home
Help & FAQ
Link opens in a new tab
English
עברית
العربية
Search content at Ariel University
Home
Profiles
Research units
Equipment
Research output
Prizes
Activities
Press/Media
Safety of infliximab use during pregnancy
Nada Djokanovic
, Chagit Klieger-Grossmann
, Anna Pupco
, Gideon Koren
Research output
:
Contribution to journal
›
Review article
›
peer-review
67
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety of infliximab use during pregnancy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
During Pregnancy
100%
Infliximab
100%
Third Trimester
22%
Infection Risk
22%
First Trimester
11%
Pregnancy Outcome
11%
Fetal Exposure
11%
Placenta
11%
Rheumatoid Arthritis
11%
Placental Transfer
11%
Vaccination
11%
Second Trimester
11%
Pregnancy Trimester
11%
Serum Levels
11%
Fetal Risk
11%
Immune System
11%
Tumor Necrosis Factor-α
11%
Normal Response
11%
First Year of Life
11%
Fatal Case
11%
Registry Study
11%
Live Virus
11%
Inflammatory Bowel Disease Arthritis
11%
IgG1 Monoclonal Antibody
11%
Immunological Risk
11%
BCG Vaccine
11%
Disseminated Fungal Infection
11%
Immunology and Microbiology
Infliximab
100%
Infectious Disease
33%
Infection
33%
Third Trimester Pregnancy
22%
Placenta
11%
Inflammatory Arthritis
11%
First Trimester Pregnancy
11%
Monoclonal Antibody
11%
Second Trimester Pregnancy
11%
Inflammatory Bowel Disease
11%
Placental Transfer
11%
Blood Level
11%
Tumor Necrosis Factor Alpha
11%
Conception
11%
BCG Vaccine
11%
Immunoglobulin G1
11%
Virus
11%
Immune System
11%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
100%
Infection
33%
Rheumatoid Arthritis
11%
Monoclonal Antibody
11%
Fatality
11%
Fetus Risk
11%
Inflammatory Bowel Disease
11%
Tumor Necrosis Factor
11%
BCG Vaccine
11%
Immunoglobulin G1
11%
Inflammatory Arthritis
11%
Vaccination
11%
Virus
11%